BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (NASDAQ:OSIR) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Osiris concerning the Company’s operations and financial prospects.

Osiris is a stem cell company engaged in the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound-care markets. The investigation is related to the Company’s October 21, 2013, disclosure that, in a letter to Osiris dated September 26, 2013, the Food and Drug Administration raised several regulatory concerns regarding certain of the Company’s human cell and tissue-based products, including the Company’s Ovation™ and Grafix® wound repair products. In a Company-issued press release, Osiris stated that it intends to submit a Biologics License Application for Grafix, as a result of the FDA’s determination that the product is a drug, which requires additional regulatory filings and a valid biologics license to be in effect before it can be lawfully marketed. Following this news, the price of Osiris shares dropped 17%, or $2.98 per share, to a closing price of $14.51 per share on October 21, 2013.

If you purchased Osiris shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.